Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Change in Receivables (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed Change in Receivables for 3 consecutive years, with -$12000.0 as the latest value for Q4 2025.

  • Quarterly Change in Receivables rose 97.29% to -$12000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$79000.0 through Dec 2025, up 92.36% year-over-year, with the annual reading at -$79000.0 for FY2025, 92.36% up from the prior year.
  • Change in Receivables for Q4 2025 was -$12000.0 at Artiva Biotherapeutics, down from $49000.0 in the prior quarter.
  • The five-year high for Change in Receivables was $933000.0 in Q3 2023, with the low at -$888000.0 in Q4 2023.
  • Average Change in Receivables over 3 years is -$106800.0, with a median of -$165500.0 recorded in 2024.
  • The sharpest move saw Change in Receivables crashed 113.61% in 2024, then skyrocketed 140.93% in 2025.
  • Over 3 years, Change in Receivables stood at -$888000.0 in 2023, then soared by 50.23% to -$442000.0 in 2024, then skyrocketed by 97.29% to -$12000.0 in 2025.
  • According to Business Quant data, Change in Receivables over the past three periods came in at -$12000.0, $49000.0, and -$204000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.